<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722930</url>
  </required_header>
  <id_info>
    <org_study_id>GOTEL-FL1LC-0701</org_study_id>
    <secondary_id>Eudra-CT 2007-003091-19</secondary_id>
    <nct_id>NCT00722930</nct_id>
  </id_info>
  <brief_title>Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma</brief_title>
  <acronym>GOTEL-FL1LC</acronym>
  <official_title>Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the complete clinical response rate according to the International Working Group
      criteria with a consolidation treatment with 90Y-ibritumomab tiuxetan (Zevalin®) in patients
      with high-risk follicular lymphoma with either partial or complete response to R-CHOP
      induction chemotherapy
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CT scan of cervical spine, chest, abdomen and pelvis, Peripheral blood and bone marrow PCR to determine Minimal Residual Disease</measure>
    <time_frame>12 weeks after consolidation, then repeated every 3 months over the first 2 years, and every 6 months thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective clinical response rate (complete + partial).</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response conversion rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complete molecular responses</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to salvage therapy</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphoma-free or specific cause-free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile and safety of the consolidation</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>1. Consolidation with Y90 Ibritumomab Tiuxetan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. Consolidation with Y90 Ibritumomab Tiuxetan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y90 Ibritumomab Tiuxetan</intervention_name>
    <description>Consolidation with Y90 Ibritumomab Tiuxetan</description>
    <arm_group_label>1. Consolidation with Y90 Ibritumomab Tiuxetan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of the written informed consent by the subject or his/her legal
             representative before initiation of any trial specific procedure.

          -  Patients older than 18.

          -  Histologic diagnosis of CD20+, grade 1-3a follicular lymphoma as per the WHO
             classification.

          -  High-risk patients according to FLIPI before initiation of induction chemotherapy.

          -  Stage II-IV prior to initiation of induction treatment, or any stage in patients with
             grade 3 follicular lymphoma.

          -  Complete or partial response to the induction scheme.

          -  ECOG scale performance status 0 - 2.

          -  Life expectancy greater than 3 months.

          -  In women of childbearing age, use of a reliable contraceptive method.

          -  A suitable bone marrow reserve:

               -  Lower than 25% Bone marrow infiltration by lymphoma.

               -  Hb 10 g/dL. PMN leukocytes 1,500 cel/mm3, platelets 100,000/mm3

               -  Suitable hepatic, renal and cardiac function:

                    -  creatinine &lt;2,5 x UNL (upper normality limit).

                    -  bilirubin or ALT/AST &lt; 2,5 x UNL

        Exclusion Criteria:

          -  Patients with no objective clinical response to induction chemotherapy.

          -  &gt; 25% bone marrow infiltration following induction chemotherapy.

          -  Platelets &lt; 100,000 before radioimmunotherapy.

          -  Severe and/or uncontrolled concomitant disease:

          -  Hepatic, renal, cardiovascular, neurological or metabolic disease.

          -  Cardiac failure, ischemic cardiopathy, ischemic cardiopathy with a history of
             myocardial infarction or angor, or major ventricular arrhythmia.

          -  Positive regarding HBV, HCV, HIV.

          -  Active acute or chronic infection.

          -  Social, psychic or geographic disability to satisfy any of the treatment schemes.

          -  Pregnant and/or breastfeeding women, or adult patients of childbearing age who are not
             using a safe birth control device throughout the study treatment and at least 12
             months thereafter.

          -  Known or suspected hypersensitivity, or confirmed or suspected adverse reaction to the
             study drugs and other related compounds (Rituximab, Ibritumomab tiuxetan, a history of
             sensitivity to murine proteins, dexametasone, cyclophosphamide and other
             anthracyclines, cytarabine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Puerta de Hierro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariano Provencio, MD</last_name>
    <phone>+34-91-344-57-60</phone>
    <email>mprovenciop@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Cerdeira, Secretary</last_name>
    <phone>34 91 3445131</phone>
    <email>secretariatecnica@grupolinfomas.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico San Sebastián</name>
      <address>
        <city>Donostia</city>
        <state>San Sebastián</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinia Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mariano Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud de Toledo</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>July 25, 2008</last_update_submitted>
  <last_update_submitted_qc>July 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Mariano Provencio</name_title>
    <organization>Clínica Puerta de Hierro, Servicio de Oncología Médica</organization>
  </responsible_party>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>High-risk FLIPI</keyword>
  <keyword>R-CHOP</keyword>
  <keyword>GOTEL</keyword>
  <keyword>Partial</keyword>
  <keyword>Complete</keyword>
  <keyword>Response</keyword>
  <keyword>Induction</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

